Anti-CDKN2A monoclonal antibody
Pre-made anti-CDKN2A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to CDKN2A/CDKN2A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T16452-Ab-1/ GM-Tg-hg-T16452-Ab-2 | Anti-Human CDKN2A monoclonal antibody | Human |
GM-Tg-rg-T16452-Ab-1/ GM-Tg-rg-T16452-Ab-2 | Anti-Rat CDKN2A monoclonal antibody | Rat |
GM-Tg-mg-T16452-Ab-1/ GM-Tg-mg-T16452-Ab-2 | Anti-Mouse CDKN2A monoclonal antibody | Mouse |
GM-Tg-cynog-T16452-Ab-1/ GM-Tg-cynog-T16452-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CDKN2A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T16452-Ab-1/ GM-Tg-felg-T16452-Ab-2 | Anti-Feline CDKN2A monoclonal antibody | Feline |
GM-Tg-cang-T16452-Ab-1/ GM-Tg-cang-T16452-Ab-2 | Anti-Canine CDKN2A monoclonal antibody | Canine |
GM-Tg-bovg-T16452-Ab-1/ GM-Tg-bovg-T16452-Ab-2 | Anti-Bovine CDKN2A monoclonal antibody | Bovine |
GM-Tg-equg-T16452-Ab-1/ GM-Tg-equg-T16452-Ab-2 | Anti-Equine CDKN2A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T16452-Ab-1/ GM-Tg-hg-T16452-Ab-2; GM-Tg-rg-T16452-Ab-1/ GM-Tg-rg-T16452-Ab-2; GM-Tg-mg-T16452-Ab-1/ GM-Tg-mg-T16452-Ab-2; GM-Tg-cynog-T16452-Ab-1/ GM-Tg-cynog-T16452-Ab-2; GM-Tg-felg-T16452-Ab-1/ GM-Tg-felg-T16452-Ab-2; GM-Tg-cang-T16452-Ab-1/ GM-Tg-cang-T16452-Ab-2; GM-Tg-bovg-T16452-Ab-1/ GM-Tg-bovg-T16452-Ab-2; GM-Tg-equg-T16452-Ab-1/ GM-Tg-equg-T16452-Ab-2 |
Products Name | Anti-CDKN2A monoclonal antibody |
Format | mab |
Target Name | CDKN2A |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-CDKN2A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T16452-Ag-1 | Recombinant multi-species CDN2A/ ARF/ CDKN2A protein |
ORF Viral Vector | pGMAD000002 | human CDKN2A Adenovirus plasmid |
ORF Viral Vector | vGMAD000002 | human CDKN2A Adenovirus particle |
ORF Viral Vector | pGMLPm000244 | mouse Cdkn2a Lentivirus plasmid |
ORF Viral Vector | vGMLPm000244 | mouse Cdkn2a Lentivirus particle |
Target information
Target ID | GM-T16452 |
Target Name | CDKN2A |
Gene ID | 1029 |
Gene Symbol and Synonyms | ARF,CDK4I,CDKN2,CDKN2A,CMM2,INK4,INK4A,MLM,MTS-1,MTS1,P14,P14ARF,P16,P16-INK4A,P16INK4,P16INK4A,P19,P19ARF,TP16 |
Uniprot Accession | P42771, Q8N726 |
Uniprot Entry Name | ARF_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | Prostate Cancer, Skin cancer - melanoma |
Gene Ensembl | ENSG00000147889 |
Target Classification | N/A |
The target: CDKN2A, gene name: CDKN2A, also named as ARF, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, TP16. This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.